ATE258379T1 - Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert - Google Patents
Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiertInfo
- Publication number
- ATE258379T1 ATE258379T1 AT94911498T AT94911498T ATE258379T1 AT E258379 T1 ATE258379 T1 AT E258379T1 AT 94911498 T AT94911498 T AT 94911498T AT 94911498 T AT94911498 T AT 94911498T AT E258379 T1 ATE258379 T1 AT E258379T1
- Authority
- AT
- Austria
- Prior art keywords
- tumor rejection
- rejection antigen
- nucleic acid
- antigen precursor
- acid coding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/032,978 US5620886A (en) | 1993-03-18 | 1993-03-18 | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
PCT/US1994/002487 WO1994021126A1 (en) | 1993-03-18 | 1994-03-09 | Nucleic acid coding for a tumor rejection antigen precursor |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE258379T1 true ATE258379T1 (de) | 2004-02-15 |
Family
ID=21867896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94911498T ATE258379T1 (de) | 1993-03-18 | 1994-03-09 | Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert |
Country Status (17)
Country | Link |
---|---|
US (2) | US5620886A (de) |
EP (1) | EP0690675B1 (de) |
JP (1) | JP3433322B2 (de) |
CN (1) | CN1072719C (de) |
AT (1) | ATE258379T1 (de) |
AU (1) | AU675707B2 (de) |
CA (1) | CA2158446C (de) |
DE (2) | DE69433518T4 (de) |
DK (1) | DK0690675T5 (de) |
ES (1) | ES2210252T3 (de) |
FI (1) | FI954360A (de) |
NO (1) | NO953601L (de) |
NZ (1) | NZ263348A (de) |
PT (1) | PT690675E (de) |
TW (1) | TW442568B (de) |
WO (1) | WO1994021126A1 (de) |
ZA (1) | ZA941812B (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856091A (en) * | 1993-03-18 | 1999-01-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
US5874560A (en) | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
CA2188432C (en) * | 1994-04-22 | 2011-02-01 | Yutaka Kawakami | Melanoma antigens |
US5997870A (en) * | 1994-06-03 | 1999-12-07 | Ludwig Institute For Cancer Research | Isolated peptides which bind to HLA-B44 Molecules |
US5821122A (en) * | 1995-06-07 | 1998-10-13 | Inserm (Institute Nat'l De La Sante Et De La Recherche . .) | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
US6096313A (en) * | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
FR2746110B1 (fr) * | 1996-03-14 | 1998-04-17 | Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants | |
US5674749A (en) * | 1996-03-26 | 1997-10-07 | Ludwig Institute For Cancer Research | Monoclonal antibodies which bind to tumor rejection antigen precursor melan-A, and uses thereof |
EP0910646A1 (de) * | 1996-06-25 | 1999-04-28 | The Ludwig Institute for Cancer Research | Glykogen phopshorylase krebsantigen aus dem gehirn |
AU6042198A (en) | 1997-01-27 | 1998-08-18 | Ludwig Institute For Cancer Research | Lage-1 tumor associated nucleic acids |
US5879892A (en) * | 1997-04-25 | 1999-03-09 | Ludwig Institute For Cancer Research | Leukemia associated genes |
CA2318979A1 (en) * | 1998-01-26 | 1999-07-29 | Genzyme Corporation | Antigen-specific cells, methods of generating these cells and uses thereof |
US6245525B1 (en) | 1998-07-27 | 2001-06-12 | Ludwig Institute For Cancer Research | Tumor associated nucleic acids and uses therefor |
US7001999B1 (en) | 1998-04-15 | 2006-02-21 | Ludwig Institute For Cancer Research | Tumor associated nucleic acids and uses therefor |
US6770456B1 (en) | 1998-07-29 | 2004-08-03 | Ludwig Institute For Cancer Research | Endogenous retrovirus tumor associated nucleic acids and antigens |
DE19913707A1 (de) * | 1999-03-26 | 2000-10-05 | Privates Inst Bioserv Gmbh | Immunadsorber zur Sepsistherapie |
JP2003512057A (ja) | 1999-10-19 | 2003-04-02 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Mage−a12抗原ペプチド及びその利用 |
US20030113919A1 (en) * | 2001-08-17 | 2003-06-19 | Aventis Pasteur, Ltd. | Immunogenic targets for melanoma |
WO2003063792A2 (en) | 2002-01-30 | 2003-08-07 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to tim-3, a th1-specific cell surface molecule |
US7311914B2 (en) * | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
US7178491B2 (en) * | 2003-06-05 | 2007-02-20 | Caterpillar Inc | Control system and method for engine valve actuator |
US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
US20060159689A1 (en) * | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
KR20070056042A (ko) * | 2004-06-17 | 2007-05-31 | 맨카인드 코포레이션 | 에피토프 유사체 |
WO2006083305A2 (en) | 2004-06-23 | 2006-08-10 | University Of Texas System | Methods and compositions for the detection of biological molecules using a two particle complex |
PL1833506T3 (pl) * | 2004-12-29 | 2016-01-29 | Mannkind Corp | Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych |
AU2006259307B2 (en) | 2005-06-17 | 2012-12-20 | Mannkind Corporation | Epitope analogues |
SG162818A1 (en) | 2005-06-17 | 2010-07-29 | Mannkind Corp | Multivalent entrain-and-amplify immunotherapeutics for carcinoma |
JP5416968B2 (ja) | 2005-06-17 | 2014-02-12 | マンカインド コーポレイション | 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物 |
US8088379B2 (en) * | 2006-09-26 | 2012-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
WO2008148068A1 (en) * | 2007-05-23 | 2008-12-04 | Mannkind Corporation | Multicistronic vectors and methods for their design |
BRPI0820270A2 (pt) | 2007-11-07 | 2015-06-16 | Celldex Therapeutics Inc | Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular. |
CA2778707A1 (en) | 2009-10-23 | 2011-04-28 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
NZ623807A (en) | 2010-04-13 | 2016-03-31 | Celldex Therapeutics Inc | Antibodies that bind human cd27 and uses thereof |
WO2015187835A2 (en) | 2014-06-06 | 2015-12-10 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
US20180044429A1 (en) | 2015-03-09 | 2018-02-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
CA2987410A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
SG11201803817PA (en) | 2015-11-19 | 2018-06-28 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
EA201892362A1 (ru) | 2016-04-18 | 2019-04-30 | Селлдекс Терапьютикс, Инк. | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
US5487974A (en) * | 1992-12-22 | 1996-01-30 | Ludwig Institute For Cancer-Research | Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells |
-
1993
- 1993-03-18 US US08/032,978 patent/US5620886A/en not_active Expired - Lifetime
-
1994
- 1994-03-09 WO PCT/US1994/002487 patent/WO1994021126A1/en active IP Right Grant
- 1994-03-09 AU AU63993/94A patent/AU675707B2/en not_active Expired
- 1994-03-09 DE DE69433518T patent/DE69433518T4/de not_active Expired - Lifetime
- 1994-03-09 CA CA002158446A patent/CA2158446C/en not_active Expired - Lifetime
- 1994-03-09 JP JP52108894A patent/JP3433322B2/ja not_active Expired - Lifetime
- 1994-03-09 DE DE69433518A patent/DE69433518D1/de not_active Expired - Lifetime
- 1994-03-09 DK DK94911498T patent/DK0690675T5/da active
- 1994-03-09 NZ NZ263348A patent/NZ263348A/en not_active IP Right Cessation
- 1994-03-09 PT PT94911498T patent/PT690675E/pt unknown
- 1994-03-09 AT AT94911498T patent/ATE258379T1/de active
- 1994-03-09 EP EP94911498A patent/EP0690675B1/de not_active Expired - Lifetime
- 1994-03-09 ES ES94911498T patent/ES2210252T3/es not_active Expired - Lifetime
- 1994-03-15 ZA ZA941812A patent/ZA941812B/xx unknown
- 1994-03-18 CN CN94103425A patent/CN1072719C/zh not_active Expired - Lifetime
- 1994-07-18 TW TW083106543A patent/TW442568B/zh not_active IP Right Cessation
-
1995
- 1995-03-03 US US08/398,409 patent/US5854203A/en not_active Expired - Lifetime
- 1995-09-13 NO NO953601A patent/NO953601L/no not_active Application Discontinuation
- 1995-09-15 FI FI954360A patent/FI954360A/fi unknown
Also Published As
Publication number | Publication date |
---|---|
DE69433518D1 (de) | 2004-03-04 |
NO953601L (no) | 1995-10-31 |
AU6399394A (en) | 1994-10-11 |
JP3433322B2 (ja) | 2003-08-04 |
EP0690675B1 (de) | 2004-01-28 |
PT690675E (pt) | 2004-06-30 |
NZ263348A (en) | 1996-06-25 |
FI954360A0 (fi) | 1995-09-15 |
CA2158446C (en) | 2009-01-06 |
US5854203A (en) | 1998-12-29 |
NO953601D0 (no) | 1995-09-13 |
ZA941812B (en) | 1994-10-13 |
CN1093406A (zh) | 1994-10-12 |
EP0690675A4 (de) | 1998-12-23 |
EP0690675A1 (de) | 1996-01-10 |
US5620886A (en) | 1997-04-15 |
CN1072719C (zh) | 2001-10-10 |
JPH08507693A (ja) | 1996-08-20 |
DE69433518T2 (de) | 2004-06-24 |
WO1994021126A1 (en) | 1994-09-29 |
TW442568B (en) | 2001-06-23 |
ES2210252T3 (es) | 2004-07-01 |
FI954360A (fi) | 1995-09-15 |
DE69433518T4 (de) | 2009-07-23 |
DK0690675T5 (da) | 2008-11-17 |
DK0690675T3 (da) | 2004-06-01 |
AU675707B2 (en) | 1997-02-13 |
CA2158446A1 (en) | 1994-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE258379T1 (de) | Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert | |
ATE267254T1 (de) | Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen | |
DE69013313D1 (de) | Mehrstufenverfahren zur Herstellung von Hexafluorpropylen. | |
PT845032E (pt) | Moleculas isoladas de acidos nucleicos peptidos que formam complexos com a molecula a2-alh do cph e suas aplicacoes | |
FI960268A0 (fi) | Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä | |
DE3778948D1 (de) | Teilchen, geeignet fuer die herstellung von tabletten als diagnostische reagenzien. | |
ZA958039B (en) | Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof | |
EA200200565A1 (ru) | Применение клеток, трансфицированных днк, кодирующей лиганд мнс класса ii, и способ получения таких клеток | |
BR9909844A (pt) | Processo para sintetizar um composto, e, composto. | |
DE69008326D1 (de) | Mehrstufenverfahren zur Herstellung von Hexafluoropropylen. | |
DE69010171D1 (de) | Mehrstufenverfahren zur Herstellung von Hexafluoropropylen. | |
DE69626789D1 (de) | Isolierte und verkürzte nukleinsäuremoleküle kodierend für gage-tumorabstossungsantigen | |
NO970030L (no) | Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2 | |
FR2357517A1 (fr) | Procede de production d'halogenophenols | |
ES2058067T3 (es) | Proceso para la produccion de 2,6-didesoxi-2-fluoro-l-talopiranosa y sus derivados. | |
DK1404844T3 (da) | Fremgangsmåde til fremstilling af 2,4-dideoxyhexoser og 2,4,6-trideoxyhyxoser | |
ES2148891T3 (es) | Procedimiento para la fabricacion de 2-metil-2,4-diaminopentano. | |
DE3780665D1 (de) | Mehrstufiges reduktionsverfahren zur herstellung von ferromagnetischem chromdioxid. | |
ATE265418T1 (de) | Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine | |
DE69004012D1 (de) | Verfahren zur Gewinnung von festen Molybdän-Verbindungen. | |
DE69617255D1 (de) | Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendung | |
EA200000705A1 (ru) | Промежуточные соединения и способ синтеза 17-замещенных 16.бета.-арилокси 4-азастероидов | |
DE68914551D1 (de) | Verfahren zur Produktion von O-silyl O,N-Keten-Acetalen. | |
TW372973B (en) | Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof | |
ES2194745T3 (es) | Procedimiento para la obtencion de 4,6-dicloropirimidi-na. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0690675 Country of ref document: EP |